Codexis IPO
Codexis is a leading enzyme engineering company that develops custom enzymes for pharmaceutical, food, and industrial applications using its proprietary CodeEvolver platform. The company's protein engineering capabilities have made it an attractive partner for major pharmaceutical companies seeking more efficient and sustainable manufacturing processes.
What We Know
Codexis went public in April 2010, raising approximately $81 million in its IPO at $13 per share. The company trades on NASDAQ under the ticker symbol CDXS and has been public for over a decade. Since going public, Codexis has experienced significant stock price volatility, with shares ranging from single digits to over $40 depending on partnership announcements and financial performance. The company has built a strong portfolio of partnerships with major pharmaceutical companies and continues to expand its enzyme engineering platform for various industrial applications.
Frequently Asked Questions
Has Codexis had an IPO?
Yes, Codexis completed its IPO in April 2010 and has been publicly traded for over a decade. The company trades on NASDAQ under the ticker CDXS.
When is the Codexis IPO date?
Codexis already completed its IPO in April 2010. The company has been publicly traded on NASDAQ for more than 13 years.
How can I buy Codexis stock?
You can buy Codexis stock through any brokerage account as it trades publicly on NASDAQ under the ticker symbol CDXS. The stock is available for purchase during regular market hours and after-hours trading.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts